Shifting Paradigms: A Surgeon’s View on the Evolution of Thyroid Management over Fifty Years

THE QUIET REVOLUTION: FIVE DECADES OF CHANGE IN THYROID SURGERY “Day by day, nothing seems to change, but pretty soon… everything’s different.” This observation by Bill Watterson perfectly encapsulates the trajectory of my career in head and neck surgery. As I reflect on my journey – from my early days as a resident walking the wards of TNMC and KEM Hospital in Mumbai to my current role at HN Reliance and Breach Candy – I realize that we have lived through a medical Kaizen. This philosophy of continuous, subtle improvement has, over fifty years, quietly dismantled the “one-size-fits-all” surgical dogma of the past, replacing it with a sophisticated, risk-stratified discipline that prioritizes the patient’s quality of life as much as the cure. A TALE OF TWO ERAS: THE CASE OF THE 25-YEAR-OLD PATIENT Consider a patient in my clinic today: a 25-year-old mother with a firm 3.5 cm × 3 cm thyroid nodule. She has no family history of malignancy and no radiation exposure. While her vocal cords are mobile, the palpable swelling represents a crossroads. Her journey today is vastly different from what it would have been when I began my career. Back then, surgery was essentially the only definitive tool we had for diagnosing malignancy in a nodule. Without the benefit of molecular testing, advanced imaging, or a nuanced understanding of risk stratification, the clinical landscape of the 1980s favored a “wide net” approach. This patient likely would have undergone total thyroidectomy, perhaps accompanied by a formal neck dissection and radioiodine therapy, regardless of the intrinsic risk of her specific tumor. We lacked the guidelines to do anything less, and the fear of “missing” a cancer drove us toward maximum intervention. As the cartoonist Bill Watterson once wrote, “day by day, nothing seems to change, but pretty soon… everything’s different.”[1] This reflection perfectly encapsulates the profound shift from those days of diagnostic uncertainty to our current era of balanced, personalized care. THE FOUNDATIONS OF STANDARDIZATION The journey toward our modern standards began with the pioneering work of Emil Theodor Kocher, who standardized safe thyroid surgery at the turn of the 20th century. His meticulous approach earned him the Nobel Prize in 1909 and established the foundational “Kai” – the change – necessary to achieve the “Zen,” or the good of the patient. This was the first great step toward precision, replacing surgical haste with anatomical respect.[2] While Kocher gave us the surgical foundation, it took decades for our diagnostic tools to evolve through the same spirit of continuous improvement. Ultrasound emerged as a primitive detection tool but has since undergone radical refinement. Today, it is a sophisticated instrument used not just for identifying cystic changes but for the meticulous characterization of nodules[3] and the long-term follow-up of papillary microcarcinomas (PMCs). Parallel to the evolution of imaging was the development of fine-needle aspiration cytology. First described in the 1930s by Martin and Ellis at Memorial Hospital in New York, the technique initially struggled for acceptance.[4] It was not until the 1960s and 1970s that Scandinavian investigators, specifically Einhorn and Franzén, firmly demonstrated its diagnostic value.[5] By 1980s, the practice was finally established in India. I remember the pivotal years at TNMC, Mumbai, where I began my career; it was during this time that our local expertise began to take shape, highlighted by the 1987 study on solitary cold nodules of the thyroid published in the Journal of Association of Physicians India, which helped ground these global advancements in the Indian clinical context.[6] THE “DIFFERENTIATED THYROID CANCER EPIDEMIC” AND THE LESSON OF SOUTH KOREA In recent decades, we have witnessed a dramatic rise in the global incidence of differentiated thyroid cancer (DTC), a phenomenon often referred to as an “epidemic.” This trend has been most pronounced in the United States and, most strikingly, in South Korea. In the South Korean context, researchers such as Ahn et al. noted in a 2014 NEJM study that the incidence skyrocketed from 12.2/100,000 between 1993 and 1997 to a staggering 59.9/100,000 between 2003 and 2007.[7] However, a critical paradox emerged while the number of cases increased nearly five-fold, the mortality rate remained almost entirely unchanged. As analyzed by Davies and Welch in their 2014 article published in the JAMA Otolaryngology,[8] this rise was not due to new environmental risk factors or a change in the biology of the disease but was instead a byproduct of “opportunistic screening.” The proliferation of advanced diagnostic imaging, including computed tomography, magnetic resonance imaging, and positron emission tomography scans, led to the detection of a large number of indolent nodules that would have otherwise remained asymptomatic throughout a patient’s life. This realization was a turning point for the surgical community, exposing the reality of overdiagnosis and the subsequent unnecessary treatment of low-risk nodules. It taught us that finding more cancer does not always mean we are saving more lives; sometimes, it simply means we are over-treating a disease that is naturally forgiving. THE PHILOSOPHY OF “LESS IS MORE”: THE GREAT SURGICAL SHIFT As a practitioner, I have always been guided by the philosophy of “Kai Zen.” In thyroid surgery, this has manifested as a move toward more balanced management. For years, a perennial squabble that was prevalent during my lifetime between the proponents of total thyroidectomy and those favoring hemithyroidectomy, a debate that stretched from the Lahey Clinic and the Mayo Clinic to the MSKCC and the Karolinska Institute.[9] The pioneering work of Dr. Jatin Shah and Dr. Ashok Shaha at MSKCC redefined thyroid surgery by introducing risk stratification and proving that lobectomy is a safe, effective option for low-risk (cT1–T2) DTC.[10] For years, the 2009 American Thyroid Association (ATA) guidelines favored a more aggressive approach – largely based on Billimoria’s National Cancer Database analysis[11] – recommending total thyroidectomy for nearly all tumors over 1 cm. However, the “Winds of Change” arrived with the 2015 update.[12] This shift was fuelled by Adam et al.’s massive meta-analysis of over 61,000 patients, which demonstrated that for 1–4 cm tumors, the extent of surgery (total vs. hemi) had no significant impact on overall survival, although hemithyroidectomy carried far fewer complications.[13] The “less is more” philosophy reached its peak in the ATA 2025 update.[14] It strongly supports hemithyroidectomy for tumors up to 2 cm (doubling the previous 1 cm threshold) and offers a choice between hemi and total for lesions in the 2–4 cm range. This decision is now driven by shared decision-making between the clinician and the patient. We have successfully moved from an aggressive “one size fits all” model to a tailored strategy, matching the surgical footprint to the actual risk of the disease. MINIMALISM IN ADJUVANTS: NECK DISSECTION AND RADIOIODINE Our move toward minimalism extends to the management of lymph nodes and the use of adjuvant therapy. Prophylactic central compartment neck dissection was once a routine consideration, but we have moved away from this practice for small, noninvasive T1 or T2 node-negative cases. Consensus statements from the British thyroid guidelines and the American Head and Neck Society[15,16] now emphasize that thyroidectomy alone is appropriate for these low-risk scenarios, reserving central compartment dissection for larger T3/T4 tumors/high risk tumors where the clinical benefit is clearer. A similar refinement has occurred with radioiodine therapy. Landmark prospective trials, specifically ESTIMABL2[17] and the IoN trial[18] – have both shown that omitting radioiodine in low-risk patients is noninferior to traditional ablation regarding recurrence-free survival. When radioiodine is necessary, we have learned to be judicious, finding 30 mCi to be as effective as 100 mCi for the specific purpose of remnant ablation. Furthermore, we now utilize dynamic risk stratification to monitor patients posttreatment. By classifying responses as excellent, indeterminate, biochemical incomplete, or structural incomplete, we can dynamically reset the initial risk category. For instance, a high-risk patient who demonstrates an excellent biochemical and structural response is effectively down-graded in their risk profile, allowing us to safely reduce the intensity of their long-term surveillance.[14] ACTIVE SURVEILLANCE: REDEFINING THE “C” WORD Perhaps, the most radical shift in our field is the adoption of active surveillance for PMCs, abbreviated as PMC. Pioneered at Kuma Hospital in Japan by Ito et al.,[19] this strategy treats certain small malignancies with conservative observation rather than immediate surgery. Their decade-long studies revealed that only 8% of these PMCs showed an increase in size and only 3.8% developed new nodal metastases. Crucially, there were zero disease-related deaths among patients in the surveillance arm, and those who eventually required surgery due to progression suffered no ill effects from the delay. Active surveillance has transitioned from an experimental concept to a mature clinical strategy accepted by international bodies including the ATA[14] and the Japanese and Korean thyroid associations.[20] While it presents psychological challenges for patients living with a known malignancy and requires significant physician buy-in, the data suggest it is a safe and effective way to avoid the morbidity of surgery in carefully selected candidates. It represents the ultimate expression of our “Less is More” philosophy, acknowledging that not every “cancer” requires a knife. TECHNOLOGICAL GUARDIANS: MOLECULAR TESTING, NERVE MONITORING Technology has become a vital guardian in our pursuit of precision. Molecular diagnostics now allow us to manage indeterminate cytology and follicular neoplasms – the Bethesda III and IV lesions – with much higher certainty. We utilize “rule-out” tests like the Afirma genomic sequencing classifier for its high negative predictive value and “rule-in” panels like ThyroSeq v3 Genomic Classifier (Sonic Healthcare USA ThyroSeq Laboratory/CBLPath, Inc., Rye Brook, NY, USA) to identify specific mutations that guide the extent of surgery, often allowing us to defer surgery altogether when a benign signature is found.[21] In the operating room, the evolution of nerve preservation has been equally significant. We have moved from the 1933 axiom of Prioleau,[22] which suggested an “RLN seen is injured,” to the 1999 principle of Wheeler,[23] which mandates the clear identification of the nerve. Intraoperative nerve monitoring has emerged as a critical risk-mitigation tool, conclusively decreasing transient vocal cord palsies.[24] It provides specific utility in high-risk scenarios such as revision surgery, thyrotoxicosis, cases with multiple central compartment lymphadenopathy, locally advanced cancer, and large goiters with retrosternal extension.[25] EVOLUTION OF REMOTE ACCESS APPROACHES We have witnessed the increasing adoption of remote-access thyroid surgery techniques, including robotic trans-axillary and retro-auricular (facelift) approaches. These methods provide excellent cosmetic outcomes with no visible neck scar, faster early postoperative recovery in selected patients, and improved appearance-related quality of life compared with conventional open thyroidectomy.[26] However, their broader adoption remains constrained by limited accessibility (particularly in nonAsian populations due to anatomical considerations and patient body habitus), a steep learning curve (typically 35–66 cases for trans-axillary robotic thyroidectomy), and significantly higher costs related to instrumentation and operative time. To achieve optimal functional (recurrent laryngeal nerve and parathyroid preservation) and oncological outcomes, these procedures should be performed by experienced surgeons in high-volume centers.[27] More recently, transoral thyroidectomy has gained interest as a truly scarless option utilizing a vestibular approach through the oral cavity. It can be performed endoscopically transoral endoscopic thyroidectomy vestibular approach (TOETVA) or with robotic assistance transoral robotic thyroidectomy (TORT).[28] In contrast to trans-axillary and retro-auricular approaches, which allow better access to the lateral neck compartments when needed, the transoral route has a key anatomical limitation in addressing lateral neck disease comprehensively. While both TOETVA and TORT consistently demonstrate excellent cosmetic results and comparable short-term oncological adequacy (in terms of lymph node yield and thyroglobulin levels) to open surgery in carefully selected patients with small, well-DTCs, we remain appropriately cautious regarding their routine use in malignancy. While initial mid-term oncological outcomes are promising, long-term recurrence and survival data are still maturing, and patient selection remains critical.[28] THE INDIAN CONTEXT: WHY INDIAN THYROID CANCER GUIDELINES MATTER As President of the Indian Society of Thyroid Surgeons, I am acutely aware that global guidelines must be viewed through a local lens. India faces unique challenges, including limited resources, a high frequency of delayed presentations, and a significant expertise gap across our vast geography. Perhaps, most distressingly, 50%–75% of Indian patients pay for cancer care out of their own pockets.[29] While modern advances are available in our metropolitan centers, they remain inaccessible to a large portion of our population due to the diversity and disparity in infrastructure and training. This disparity necessitated the creation of the specific Indian Thyroid Cancer Guidelines, published in January 2024.[30] These guidelines address our unique infrastructure and clinical philosophy, emphasizing that precision must be matched by practicality. It is our professional responsibility to bridge the expertise gap and ensure that the “Less is More” philosophy is implemented in a way that respects the socio-economic realities of our patients. We are not just treating a disease; we are treating a person within a specific, often resource-constrained, environment. CONCLUSION: A FORGIVING DISEASE WITH UNFORGIVING COMPLICATIONS The trajectory of thyroid surgery over the last half-century has been a steady march toward balance and surgical maturity. We are looking toward a future where Artificial Intelligence assists in ultrasound interpretation, liquid biopsies potentially replace invasive needles for monitoring recurrence, and transoral scarless surgery becomes a standard offering. However, as we embrace these Kai Zen improvements, we must remain grounded in the reality of our craft. Thyroid cancer is often described as a “forgiving disease” because of its generally excellent prognosis. However, the complications of our treatment – permanent nerve damage or lifelong hypocalcemia – are “unforgiving.” Our journey from the aggressive practices of the 1980s to the precision of the 2020s has been defined by a singular, humbling realization: our primary goal is not just to cure the cancer, but to preserve the quality of the life we have saved. We continue to improve, day by day, ensuring that the “Zen” of our practice always serves the “Kai” of our progress. I thank you for your patient reading. Disclosure This material has never been published and is not currently under evaluation in any other peer reviewed publication. Ethical approval Not applicable. Informed consent Not applicable. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.